EyeWorld

3 weeks ago | eyeworld.org | Susan Steury

Alcon received FDA approval for TRYPTYR, a first-in-class TRPM8 receptor agonist formerly known as AR-15512, that stimulates natural tear production for treatment of dry eye disease (DED). According to the company’s press release, this neuromodulator stimulates corneal nerves to increase natural tears. The FDA’s approval is supported by Phase 3 clinical trials that included 930 patients with dry eye disease who were randomized 1:1 to receive TRYPTYR or vehicle.

3 weeks ago | eyeworld.org | Susan Steury

by Liz HillmanEditorial Co-DirectorThe second Business of Refractive Cataract Surgery (BRiCS) Summit will take place October 3–5 in Chicago, Illinois, giving a new set of surgeon-implementor teams the opportunity to gain insights and resources to enhance their advanced-technology IOL practice.

3 weeks ago | eyeworld.org | Susan Steury

by Susanne Hewitt, MDASCRS Government Relations Committee Chair At the 2025 ASCRS Annual Meeting, the focus extended beyond the operating room and into the halls of government. With healthcare policy continuing to shape the delivery of ophthalmic care, ASCRS highlighted its Government Relations and political action committee (eyePAC) efforts throughout the meeting, emphasizing the importance of member engagement in advocacy.

4 weeks ago | eyeworld.org | Susan Steury

Iolyx Therapeutics announced topline data from its Phase 2 trial evaluating ILYX-002, a topical immunomodulator for treatment of moderate to severe dry eye disease associated with systemic or inflammatory conditions.

1 month ago | eyeworld.org | Susan Steury

Atia Vision received approval from the FDA to begin a feasibility clinical study with its OmniVu Lens System. According to the company, this dual-optic lens is designed to offer a more natural, accommodative range of vision. The lens consists of a fluid-filled, shape-changing base for focusing power and a front optic that gives the patient their needed optical power.